C12N 2740/14043
Viral genome or elements thereof as genetic vector
Official title: viral genome or elements thereof as genetic vector
C12N2740/14043 (Viral genome or elements thereof as genetic vector) appears on 15 US grants and 16 published applications in this corpus.
Search patents in C12N- Granted patents
- 15
- Published applications
- 16
- Assignees
- 26
- Inventors
- 51
- Latest grant
- 5 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 2 | 0 |
| 2002 | 1 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 1 |
| 2005 | 0 | 1 |
| 2006 | 0 | 2 |
| 2007 | 2 | 0 |
| 2008 | 0 | 1 |
| 2009 | 0 | 0 |
| 2010 | 1 | 2 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 1 | 0 |
| 2014 | 1 | 2 |
| 2015 | 0 | 0 |
| 2016 | 1 | 1 |
| 2017 | 0 | 0 |
| 2018 | 1 | 0 |
| 2019 | 0 | 1 |
| 2020 | 0 | 0 |
| 2021 | 1 | 1 |
| 2022 | 0 | 1 |
| 2023 | 0 | 0 |
| 2024 | 1 | 1 |
| 2025 | 0 | 1 |
| 2026 | 1 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Promoter having high activity in activated T-cell5 May 2026US 12,618,066 B2Shanghai Cell Therapy Group Co., Ltd.
- Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating Krebs cycle and therapeutic uses thereof3 Sep 2024US 12,077,785 B2Sotio Biotech Inc.
- Vaccine against bovine leukemia virus26 Oct 2021US 11,154,611 B2Instituto Nacional De Tecnologia Agropecuaria
- Vaccine against bovine leukemia virus24 Jul 2018US 10,029,006 B2Instituto Nacional De Technologia Agropecuaria
- Primate T-lymphotropic viruses6 Sep 2016US 9,435,000 B2The Johns Hopkins University
- Dual targeted gene therapy17 Sep 2026US 2026/0275377 A1Kelonia Therapeutics, Inc.
- Non-replicating bovine infectious lymphoma virus (blv) and cells for producing same21 Aug 2025US 2025/0263740 A1The University of Tokyo
- Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating krebs cycle and therapeutic uses thereof14 Nov 2024US 2024/0376442 A1Sotio Biotech Inc.
- Promoter having high activity in activated t-cell24 Nov 2022US 2022/0372481 A1Shanghai Cell Therapy Group Co., Ltd.
- Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating krebs cycle and therapeutic uses thereof28 Oct 2021US 2021/0332334 A1SOTIO a.s.
Most cited
By later US patents